Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.

A toolkit, developed by Treatment Action Group, is designed to facilitate community participation in the development and review of clinical trials protocols.

A report, released by RESULTS UK, makes the case for accountability within the global TB response, highlighting the lack of progress against the 2018 global commitments and the role of accountability within these commitments.

A policy brief outlines recommendations for G20 members to act together to accelerate TB vaccine development.

A one-pager, developed by TB Vax ARM, provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research.

Global Drug Facility announces an agreement with Johnson & Johnson for access to affordable generic versions of bedaquiline; Treatment Action Group, Médecins Sans Frontières and Partners in Health release statements in response to the agreement.

Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.

100 sponsored registrations will be offered to civil society members, individuals involved in efforts to address lung health, and survivors of TB. Deadline for application: 25 July 2023

A guide for affected community and civil society organizations, national TB programs and policy-makers in eastern Europe and central Asia

The Stop TB Partnership launches the Challenge Facility for Civil Society Round 12 with USD 13.5 million in funding for civil society and communities from high TB burden countries.